Transthyretin (ATTR) Amyloidosis
View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.
Congresses
Transthyretin Amyloidosis (ATTR)
RNA Therapeutics Symposium (RNATx) 2026
Transthyretin Amyloidosis (ATTR)
Peripheral Nerve Society (PNS) 2026
Transthyretin Amyloidosis (ATTR)
Heart Failure Association (HFA) 2026
Transthyretin Amyloidosis (ATTR)
American Academy of Neurology (AAN) 2026
Transthyretin Amyloidosis (ATTR)
American College of Cardiology (ACC) 2026
Transthyretin Amyloidosis (ATTR)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025
Publications
Transthyretin Amyloidosis (ATTR)
Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial
European Journal of Heart Failure
Transthyretin Amyloidosis (ATTR)
Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis
Clinical Pharmacokinetics
Transthyretin Amyloidosis (ATTR)
Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B
JACC: Asia
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B
Journal of Cardiac Failure
Transthyretin Amyloidosis (ATTR)
Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE
Clinical Medicine Insights: Cardiology
